Wednesday, September 23, 2020

Blowing up Neural Repair for Stroke Recovery

 So instead of throwing up your hands in defeat create a strategy and you can solve the neuroprotection problem also. Here is my take and I'm not medically trained and a stroke survivor so I don't accept defeat. And I considered Dr. Carmichael a rock star.

Damn it all: stroke is easy; 5 steps.
1.  Describe the problems exactly. There are tens of thousands of pieces of research already hinting at solutions, just need followup.
2.  Write thousands of RFPs to researchers/MIT grads to solve those problems.
3.  Fund them with foundation grants.
4.  Write stroke rehab protocols based on the research.
5.  Get the Nobel prize in medicine. 

Blowing up Neural Repair for Stroke Recovery

Preclinical and Clinical Trial Considerations
Originally publishedhttps://doi.org/10.1161/STROKEAHA.120.030486Stroke. ;0

The repair and recovery of the brain after stroke is a field that is emerging in its preclinical science and clinical trials. However, recent large, multicenter clinical trials have been negative, and conflicting results emerge on biological targets in preclinical studies. The coalescence of negative clinical translation and confusion in preclinical studies raises the suggestion that perhaps the field of stroke recovery faces a fate similar to stroke neuroprotection(Wrong name, it really is the neuronal cascade of death; words matter, use the term that signifies immediate action needed!), with interesting science ultimately proving difficult to translate to the clinic. This review highlights improvements in 4 areas of the stroke neural repair field that should reorient the field toward successful clinical translation: improvements in rodent genetic models of stroke recovery, consideration of the biological target in stroke recovery, stratification in clinical trials, and the use of appropriate clinical trial end points.

Footnotes

The opinions expressed in this article are not necessarily those of the editors or of the American Heart Association.

For Sources of Funding and Disclosures, see page 3172.

Correspondence to: S. Thomas Carmichael, MD, PhD, David Geffen School of Medicine at UCLA, Los Angeles, CA. Email
 

No comments:

Post a Comment